Expand your knowledge of canine osteoarthritis (OA) and how Galliprant® (grapiprant tablets) effectively treats OA inflammation and pain.
Browse our OA and Galliprant resources with the following downloadable content.
See full prescribing information in the product label.
Download a series of images and educational content to create posts that you can share on your own social channels.
Learn more about the importance of addressing inflammation in canine OA and how Galliprant is specifically designed to manage it.
Clinic reference on the importance of addressing inflammation for canine OA treatment.
Discover why experts recommend daily NSAID therapy as the cornerstone of OA treatment.
A playlist of YouTube videos with vet stories and pet owner perspectives discussing OA inflammation and pain.
Learn about an innovative staging system for canine OA, developed by a group of international experts in veterinary surgery and pain management.
Download this interactive staging tool, which will take you through the process one step at a time and automatically calculate the COAST stage of OA for your canine patients.
Download this interactive version of the LOAD questionnaire for dog owners to fill out while in the clinic. For your convenience, the final LOAD score is automatically calculated. Please note this document is not compatible with mobile devices.
Galliprant is an NSAID that controls pain and inflammation associated with osteoarthritis in dogs.
Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.
Contact your Elanco or distributor representative, or call Elanco (1-888-545-5973) to discover how you can incorporate Galliprant into your canine OA protocol today.
© 2022 Elanco or its affiliates. Galliprant, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.